Omeros Corporation
Update in progressOMER (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Omeros is a clinical-stage biopharmaceutical company developing small-molecule and protein therapeutics and orphan indications that target immunologic diseases. Its lead candidate, Narsoplimab (OMS721/MASP-2), targets TA-TMA and is in Phase II for COVID-19 and ARDS. OMS1029 (Phase I) targets MASP-2 disorders; OMS527 (Phase I) covers addictions, movement disorders, and cocaine use. Preclinical programs include MASP-2, MASP-3 inhibitors, OncotoX-AML, and Targeted Complement Activating Therapy. Based in Seattle, founded 1994.
Company score
- Sentiment
- 0.56
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.56
- Governance
- -0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.16
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.36
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEODr. Gregory A. Demopulos M.D.
- Founded1994
- Employees175
- Websitewww.omeros.com
Identifiers
- ISINUS6821431029
- FIGIBBG000JLP4B4
- LEI549300CJWLXX2MXVVV71
- CUSIP682143102
- CIK0001285819